Guides
Women's-health guides to GLP-1
GLP-1 for PCOS, the perimenopause transition, pregnancy and nursing — every clinical figure cited to its trial or FDA label. Looking for a provider instead? Every one we score is on the provider reviews page.
Women's-health guides
Search by what you are actually asking, or narrow to a topic. Guides are filed by hand, so a piece about avoiding conception is not shelved under trying for one.
Showing 60 of 60 guides
GLP-1 and Breastfeeding: What the Label Actually Says
The injectable GLP-1 labels do not tell nursing mothers to stop. Exactly one GLP-1 product does — and it is not the one you would guess.
Read the guide →GLP-1 After a Gestational-Diabetes Pregnancy
Gestational diabetes signals long-term type-2 risk. What the evidence shows — and where GLP-1 care fits once pregnancy and nursing are behind you.
Read the guide →GLP-1 and Perimenopausal Weight: The Still-Cycling Years
In the transition — still cycling, HRT-curious, contraception still needed — the body changes for real reasons.
Read the guide →When Can You Start a GLP-1 After Birth? A Timing Guide
The clock that actually governs this is the pre-pregnancy washout, not a nursing ban. A step-by-step way to sequence when a GLP-1 fits after a baby.
Read the guide →Semaglutide vs Tirzepatide for Mothers
The head-to-head trial, both placebo arms, what happens when you stop, and the three label differences between the molecules that matter for mothers.
Read the guide →How to Choose a GLP-1 Provider as a Busy Mom
A practical, evidence-first checklist for choosing GLP-1 care that respects a mother's reality — oversight and honest cost over teaser pricing.
Read the guide →Is It Safe to Take a GLP-1 While Breastfeeding? What the Evidence Says
Both semaglutide and tirzepatide have now been measured in human milk. What those studies found, what they cannot tell you, and where that leaves you.
Read the guide →Semaglutide and GLP-1s for PCOS: The Evidence
GLP-1s produce real, modest weight loss in PCOS — but they're off-label and the reproductive benefits stay uncertain. The RCTs, read honestly.
Read the guide →GLP-1s After Menopause: Weight, Visceral Fat, and Heart Risk
After the final period, fat shifts deep into the abdomen and heart risk climbs. What the evidence says about GLP-1s for post-menopausal women.
Read the guide →GLP-1s Postpartum: Timing, Safety, and the Evidence
What the labels, the milk studies and post-gestational-diabetes risk actually say about fitting a GLP-1 into the first year after birth.
Read the guide →Bone Density and Lean Mass on GLP-1s: What the DXA Trials Actually Show
Rapid weight loss costs bone, whatever causes it. What the DXA substudy, the one randomized bone-density trial, and the fracture data show for women.
Read the guide →GLP-1s, the Menstrual Cycle, and Reproductive Hormones: What the Evidence Shows
GLP-1s can shift cycles, ovulation, and fertility, mostly by driving weight loss. The mechanisms, the PCOS trial data, and the contraception caveats.
Read the guide →Breast Changes and Mammograms During GLP-1 Weight Loss: What to Know
Rapid weight loss shrinks breast fat and changes how tissue reads on a mammogram. The honest evidence on density, screening accuracy and cancer risk.
Read the guide →"Ozempic Face" and Skin Changes: What the Evidence Actually Shows
The gaunt look after rapid GLP-1 weight loss is real and has a clear mechanism. What has been measured, in how few people, and what actually helps.
Read the guide →The Next Generation of GLP-1s: Orforglipron, Retatrutide, CagriSema, and Oral Semaglutide
Two of these four are now FDA-approved. The trial evidence for orforglipron, oral semaglutide, retatrutide and CagriSema — every figure with its placebo arm.
Read the guide →Zepbound vs Wegovy: Which Is Right for a Mother?
Zepbound is injection-only; Wegovy now comes as a daily tablet too. The head-to-head result, the economics, and the label gaps that decide it for mothers.
Read the guide →Microdosing GLP-1s for Mothers: What the Evidence Says
What microdosing a GLP-1 actually means, what the dose-response data show, who it might suit — and the honest gap: no trial has tested it.
Read the guide →Hair Loss on GLP-1s: What Mothers Should Know
How often it happens by the label's own numbers, why women are affected far more than men, the telogen-effluvium timeline, and what actually helps.
Read the guide →Managing GLP-1 Side Effects When You're Also Running a Household
The nausea, constipation, and reflux are real — and mostly manageable. What actually helps day to day, and the symptoms that mean call your clinician.
Read the guide →Constipation on a GLP-1: The One Side Effect That Doesn't Climb With Your Dose
Nausea, vomiting and diarrhea all climb with dose in the trials. Constipation does the opposite — 17% at 5 mg, 11% at 15 mg. What that does and doesn't mean.
Read the guide →Heart Rate on a GLP-1: Why the Average Hides the Number That Matters
The average rise is 1–4 bpm, which is why nobody mentions it. But 26% of adults had a 20+ bpm jump at some visit, and the label says when to stop the drug.
Read the guide →Wegovy Is Now Approved for Fatty Liver Disease. Read the Word 'Accelerated'.
Semaglutide resolved steatohepatitis in 62.9% against 34.3% on placebo. A real approval, granted on an interim readout — and menopause roughly doubles the risk.
Read the guide →Yeast Infections and UTIs on a GLP-1: What the Evidence Actually Shows
Thousands of women search this every month. The genital-infection warning belongs to a different diabetes drug class — here is what the GLP-1 labels do say.
Read the guide →GLP-1s and Your Teeth: Erosion, Dry Mouth and Breath, by the Evidence
“Ozempic teeth” is a panic term, and the real dental risk is indirect. What the labels report, what erosion actually comes from, and one surprising finding.
Read the guide →GLP-1s and Sex Drive: What the Evidence Supports, and What It Does Not
Desire, arousal and function on a GLP-1 — separating the drug from the weight loss from the life. What one 2026 review found, and where the data stops.
Read the guide →Gallstones on a GLP-1: The Numbers, and Why They Matter More for Women
One of the best-quantified risks on these drugs — 76 trials, 103,371 patients — and the weight-loss doses roughly double it. What to watch for, precisely.
Read the guide →Coming Off a GLP-1: Maintenance, Rebound Weight, and How to Keep It Off
Most of the weight comes back when you simply stop — and that's biology, not failure. What the withdrawal trials show and how mothers plan around it.
Read the guide →GLP-1s and Birth Control: Does Zepbound or Ozempic Affect the Pill?
Tirzepatide carries a real FDA warning that the pill can work less well; injectable semaglutide does not.
Read the guide →Ozempic for PCOS: Does It Actually Work — and Is It Even Approved?
Ozempic isn't approved for PCOS — every use is off-label. What the trials really show for weight, cycles and fertility, and how it compares to metformin.
Read the guide →Trying to Conceive on a GLP-1: Washout Timing and the Fertility Evidence
GLP-1s aren't used in pregnancy, so conception means a planned washout. The stop-before-pregnancy window, the ovulation science, and the honest.
Read the guide →GLP-1s and Pregnancy: What to Know if You're Planning — or if You Conceive While on One
GLP-1s aren't used in pregnancy. The animal safety signal, what the large human studies actually found, and a calm plan if you conceive while taking one.
Read the guide →GLP-1s and Your Thyroid: What Mothers Should Know
The thyroid-cancer boxed warning, what the human data really show, and how a GLP-1 fits with Hashimoto's, hypothyroidism, and your levothyroxine.
Read the guide →Muscle Loss on a GLP-1: Why It Matters for Women, and How to Protect It
A real share of GLP-1 weight loss is muscle, and it matters more for women over 40. What the training and protein trials actually found, with the numbers.
Read the guide →GLP-1s and Antidepressants: What Mothers on an SSRI Should Know
Is it safe to take a GLP-1 with an SSRI? The interaction question, the additive nausea, the mental-health safety data, and what to tell your prescriber.
Read the guide →Sleep Apnea, GLP-1s, and Why Women Get Missed
Tirzepatide cut apnea events by 20 to 24 an hour more than placebo across two trials. The harder problem is that women with sleep apnea rarely get diagnosed.
Read the guide →What a GLP-1 Actually Costs a Mother, With and Without Insurance
Medicare now covers GLP-1s at $50 a month. Employer coverage runs 16-43% by company size. And the advertised self-pay price is the starting dose.
Read the guide →GLP-1s and Surgery: What the Aspiration Evidence Actually Shows
Food is left in the stomach far more often despite correct fasting, yet no rise in actual aspiration has been detected. Both are true, and the gap matters.
Read the guide →GLP-1s and Alcohol: What the Evidence Actually Says
Four randomized trials, two national cohorts, and a label that never mentions drinking. What is actually known about GLP-1s and alcohol.
Read the guide →GLP-1s and Disordered Eating: What Is Known, and What Isn't
What the research shows about GLP-1s and binge eating, restriction and eating-disorder risk — and where the evidence runs out entirely.
Read the guide →Protein, Iron and B12: Nutrient Status During Rapid Weight Loss on a GLP-1
Most GLP-1 nutrition advice is borrowed from bariatric surgery, because the trials never measured what anyone ate. Here is what is actually known.
Read the guide →"Ozempic Butt": What Actually Happens, and What the Evidence Says You Can Do
Flattening and volume loss through the hips and buttocks after fast GLP-1 weight loss. The mechanism, whether it is drug-specific, and what genuinely helps.
Read the guide →Vaginal Dryness, Irritation and Unexpected Bleeding on a GLP-1
Dryness, soreness, thrush and unexpected bleeding on a GLP-1 — what is plausibly the drug, what is the weight loss, and the one symptom to act on today.
Read the guide →Mood Changes and Emotional Blunting on a GLP-1: What the Evidence Shows
Irritability, low mood and the flatness people describe on a GLP-1. What the randomized data measured, what the label now says, and what nobody has studied.
Read the guide →Vision Changes on a GLP-1: What the NAION Evidence Actually Shows
Europe added an eye warning to semaglutide; the US label has not. Two 2026 meta-analyses disagree — and the signal sits in diabetes, not weight loss.
Read the guide →Loose Skin After GLP-1 Weight Loss: What Determines It, and What Actually Helps
How much loose skin you get is mostly determined by how much weight you lose. What the post-bariatric evidence shows, and what has never been tested.
Read the guide →GLP-1s and Endometriosis: An Interesting Lead, Not a Treatment
Zero randomized trials, one striking peritoneal-fluid finding, and a real but indirect obesity link — what the evidence supports and what it does not.
Read the guide →Taking a GLP-1 and Hormone Therapy at the Same Time
One cohort asked whether hormone therapy changes how well semaglutide works. It found a difference — and it is weaker evidence than it sounds.
Read the guide →Does a GLP-1 Cause Acne, or Does Losing Weight?
Breaking out since starting? The meta-analysis says the drug is unlikely to be the cause — which points at something more useful.
Read the guide →Testosterone Therapy and a GLP-1 at the Same Time
He is on testosterone therapy and starting a GLP-1. No trial has tested the combination — and one study suggests he may not need both.
Read the guide →The Luteal Week on a GLP-1
Appetite rises about 168 kcal a day in the luteal phase. What that means on a GLP-1 — and why timing your shot to your cycle does not follow.
Read the guide →Can You Still Orgasm on a GLP-1?
Desire and orgasm are different functions. The only direct evidence in women is one case report — and the best proxy data carry one large exception.
Read the guide →Sleep Apnea and Sex in Women
Apnea in women is treated as a snoring problem. The evidence links it to sexual dysfunction at more than double the odds — and treating it moved his scores too.
Read the guide →Does Desire Come Back After You Stop?
Nobody has studied what happens to libido after stopping a GLP-1. Here is what the withdrawal research does establish, and how to reason from it honestly.
Read the guide →Testosterone for Low Desire in Women
There is a clinical practice guideline for this, and it is narrower than the internet suggests. Who it is actually for, and the test that cannot diagnose it.
Read the guide →The GLP-1 Pill Reports Hair Loss in 7% of Women and 0.9% of Men
Foundayo's label breaks hair loss out by sex, instructs backup contraception six separate times, and caps at a dose the headlines never mention.
Read the guide →The Biggest Number Behind “Food Noise” Comes From Asking People to Remember
The headline food-noise study asked women already on semaglutide to recall how they used to feel. What is actually established, and what is not.
Read the guide →The Wegovy Pill and the Wegovy Shot Are One Label, One Blood Level, and Ten Times the Milligrams
The tablet and the injection reach almost the same blood level. The pill needs 25 mg daily to do it, and an empty stomach. What that changes for you.
Read the guide →Your Stomach Is Probably Not Paralyzed: What the Gastric-Emptying Trials Found About Bloating
The standard explanation for GLP-1 bloating is a slowed stomach. Two controlled trials measured it and found overall emptying close to normal.
Read the guide →Itching, Rash and the One Skin Reaction That Means Stop the Drug
Skin reactions on a GLP-1 are reported more often in women and are still uncommon. Where the line sits between a nuisance and a reason to stop.
Read the guide →Can You Inject a GLP-1 Into a Stretch Mark? What the Anatomy Says and the Research Has Not Asked
Two different questions get asked here: whether the drug causes stretch marks, and whether you can inject into one. The answers are not the same.
Read the guide →
Our guides are editorial, written per our methodology, with every clinical figure cited to its trial or FDA label. Not medical advice.